Rhumbline Advisers Acquires 7,389 Shares of Paratek Pharmaceuticals, Inc. (PRTK)
Rhumbline Advisers raised its holdings in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 37.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,102 shares of the specialty pharmaceutical company’s stock after purchasing an additional 7,389 shares during the period. Rhumbline Advisers owned 0.10% of Paratek Pharmaceuticals worth $653,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in PRTK. C WorldWide Group Holding A S lifted its holdings in shares of Paratek Pharmaceuticals by 449.3% in the second quarter. C WorldWide Group Holding A S now owns 439,400 shares of the specialty pharmaceutical company’s stock valued at $10,590,000 after purchasing an additional 359,400 shares in the last quarter. Pictet Asset Management Ltd. purchased a new stake in shares of Paratek Pharmaceuticals in the second quarter valued at about $6,957,000. Renaissance Technologies LLC lifted its holdings in shares of Paratek Pharmaceuticals by 275.9% in the first quarter. Renaissance Technologies LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock valued at $7,979,000 after purchasing an additional 304,249 shares in the last quarter. Marshall Wace North America L.P. purchased a new stake in shares of Paratek Pharmaceuticals in the first quarter valued at about $3,258,000. Finally, MARSHALL WACE ASIA Ltd purchased a new stake in shares of Paratek Pharmaceuticals in the first quarter valued at about $3,258,000. 82.33% of the stock is currently owned by institutional investors.
A number of equities analysts have recently weighed in on PRTK shares. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price objective on shares of Paratek Pharmaceuticals in a research report on Thursday, September 21st. ValuEngine lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. Raymond James Financial, Inc. reissued a “strong-buy” rating and issued a $36.00 price objective on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. BidaskClub lowered shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. Finally, Zacks Investment Research lowered shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Paratek Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $37.44.
Paratek Pharmaceuticals, Inc. (PRTK) opened at 25.10 on Friday. The stock has a 50 day moving average of $23.26 and a 200-day moving average of $21.71. The firm’s market cap is $696.80 million. Paratek Pharmaceuticals, Inc. has a 52-week low of $9.80 and a 52-week high of $29.00.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.25. The firm had revenue of $7.51 million during the quarter, compared to analyst estimates of $7.50 million.
COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/rhumbline-advisers-acquires-7389-shares-of-paratek-pharmaceuticals-inc-prtk/1600074.html.
In other Paratek Pharmaceuticals news, VP Adam Woodrow sold 3,800 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total value of $89,604.00. Following the completion of the transaction, the vice president now directly owns 69,500 shares in the company, valued at $1,638,810. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Chairman Michael Bigham sold 5,075 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total transaction of $119,668.50. Following the completion of the transaction, the chairman now owns 109,500 shares of the company’s stock, valued at $2,582,010. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,365 shares of company stock valued at $409,467. Corporate insiders own 4.90% of the company’s stock.
Paratek Pharmaceuticals Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.